Increased TGF-β in the tumor microenvironment predicts adverse outcomes in CRC patients, partly due to the TGF-β-induced immune evasion mechanism that promotes T cell exclusion and blocks the acquisition of the Th1 effector phenotype [28]. The gene discussed is TGFB1; the disease is neoplasm.